JP2019532970A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532970A5 JP2019532970A5 JP2019521706A JP2019521706A JP2019532970A5 JP 2019532970 A5 JP2019532970 A5 JP 2019532970A5 JP 2019521706 A JP2019521706 A JP 2019521706A JP 2019521706 A JP2019521706 A JP 2019521706A JP 2019532970 A5 JP2019532970 A5 JP 2019532970A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- complementarity determining
- dose
- chain complementarity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022173528A JP7562074B2 (ja) | 2016-10-24 | 2022-10-28 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
| JP2024153940A JP2024170569A (ja) | 2016-10-24 | 2024-09-06 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411783P | 2016-10-24 | 2016-10-24 | |
| US62/411,783 | 2016-10-24 | ||
| PCT/IB2017/001427 WO2018078442A2 (en) | 2016-10-24 | 2017-10-24 | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173528A Division JP7562074B2 (ja) | 2016-10-24 | 2022-10-28 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532970A JP2019532970A (ja) | 2019-11-14 |
| JP2019532970A5 true JP2019532970A5 (https=) | 2020-12-03 |
Family
ID=60957345
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521706A Withdrawn JP2019532970A (ja) | 2016-10-24 | 2017-10-24 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
| JP2022173528A Active JP7562074B2 (ja) | 2016-10-24 | 2022-10-28 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
| JP2024153940A Pending JP2024170569A (ja) | 2016-10-24 | 2024-09-06 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173528A Active JP7562074B2 (ja) | 2016-10-24 | 2022-10-28 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
| JP2024153940A Pending JP2024170569A (ja) | 2016-10-24 | 2024-09-06 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3528845A2 (https=) |
| JP (3) | JP2019532970A (https=) |
| KR (2) | KR20240148970A (https=) |
| CN (1) | CN110167593A (https=) |
| AU (2) | AU2017352033A1 (https=) |
| BR (1) | BR112019008156A2 (https=) |
| CA (2) | CA3244670A1 (https=) |
| EA (1) | EA201990930A1 (https=) |
| IL (1) | IL266174B2 (https=) |
| MX (2) | MX2019004766A (https=) |
| SG (1) | SG11201903659WA (https=) |
| WO (1) | WO2018078442A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121588213A (zh) | 2015-05-07 | 2026-03-03 | 瑞典孤儿比奥维特鲁姆股份公司 | 用于诊断和治疗cxcl9和其它生物标志物水平升高的患者的病症 |
| US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
| WO2017186121A1 (zh) * | 2016-04-26 | 2017-11-02 | 科济生物医药（上海）有限公司 | 一种改善免疫应答细胞功能的方法 |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| WO2021185832A1 (en) | 2020-03-16 | 2021-09-23 | Swedish Orphan Biovitrum Ag | New therapeutic treatment |
| JP2023521519A (ja) * | 2020-04-06 | 2023-05-24 | セレディット エルエルシー | キメラ抗原受容体を発現し低減した炎症性サイトカインシグナル伝達を有する遺伝子改変された免疫細胞 |
| WO2024254401A1 (en) | 2023-06-09 | 2024-12-12 | Children's Hospital Medical Center | Treatment of stem cell graft failure |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP2002531466A (ja) * | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス， インコーポレイテッド | γ−インターフェロンに対するヒト化抗体 |
| JP5290489B2 (ja) * | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Ｉｇｇ抗体の安定な液体医薬製剤 |
| MX2007008719A (es) * | 2005-01-27 | 2007-09-11 | Novimmune Sa | Anticuerpos anti-interferon gamma y metodos de uso de los mismos. |
| AU2006247039B2 (en) * | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| KR101247418B1 (ko) | 2007-12-21 | 2013-03-25 | 에프. 호프만-라 로슈 아게 | 항체 제형 |
| US20130142809A1 (en) * | 2011-11-23 | 2013-06-06 | Andrew A. Welcher | METHODS OF TREATMENT USING AN IFN gamma INHIBITOR |
| JPWO2015190378A1 (ja) | 2014-06-10 | 2017-04-20 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 安定なアダリムマブ水性製剤 |
| CN121588213A (zh) * | 2015-05-07 | 2026-03-03 | 瑞典孤儿比奥维特鲁姆股份公司 | 用于诊断和治疗cxcl9和其它生物标志物水平升高的患者的病症 |
-
2017
- 2017-10-24 EP EP17829009.4A patent/EP3528845A2/en active Pending
- 2017-10-24 CA CA3244670A patent/CA3244670A1/en active Pending
- 2017-10-24 WO PCT/IB2017/001427 patent/WO2018078442A2/en not_active Ceased
- 2017-10-24 CN CN201780080221.6A patent/CN110167593A/zh active Pending
- 2017-10-24 MX MX2019004766A patent/MX2019004766A/es unknown
- 2017-10-24 CA CA3041434A patent/CA3041434A1/en active Pending
- 2017-10-24 IL IL266174A patent/IL266174B2/en unknown
- 2017-10-24 AU AU2017352033A patent/AU2017352033A1/en not_active Abandoned
- 2017-10-24 SG SG11201903659WA patent/SG11201903659WA/en unknown
- 2017-10-24 KR KR1020247033365A patent/KR20240148970A/ko not_active Ceased
- 2017-10-24 EA EA201990930A patent/EA201990930A1/ru unknown
- 2017-10-24 JP JP2019521706A patent/JP2019532970A/ja not_active Withdrawn
- 2017-10-24 KR KR1020197014837A patent/KR20190071785A/ko not_active Ceased
- 2017-10-24 BR BR112019008156-9A patent/BR112019008156A2/pt unknown
-
2019
- 2019-04-24 MX MX2025012950A patent/MX2025012950A/es unknown
-
2022
- 2022-10-28 JP JP2022173528A patent/JP7562074B2/ja active Active
-
2024
- 2024-09-06 JP JP2024153940A patent/JP2024170569A/ja active Pending
- 2024-11-12 AU AU2024264563A patent/AU2024264563A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532970A5 (https=) | ||
| CN114286828A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| IL270253B1 (en) | Stable formulations of PROGRAMMED DEATH RECEPTOR 1 (PD–1) antibodies and methods of using them | |
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| KR102104296B1 (ko) | 종양성 질병들에 대한 치료 | |
| JP2014114288A5 (https=) | ||
| JP2018515493A5 (https=) | ||
| AU2015313827C1 (en) | Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| JP2020502219A5 (https=) | ||
| JP2019519584A5 (https=) | ||
| JP2026001086A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| WO2025002280A1 (en) | Combination therapies for the treatment of cancer | |
| US20250025583A1 (en) | Method of treatment of neuroendocrine tumors | |
| BR112020008375A2 (pt) | métodos de reduzir efeitos colaterais de terapia conjugada com fármacos de anticorpo anti-cd30 | |
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| TW202319073A (zh) | 用於治療肺癌的組合療法 | |
| CN116113411A (zh) | 用于治疗软组织肉瘤的联用药物 | |
| CN121548431A (zh) | 包含偶联物的药物组合的治疗方法和用途 | |
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| KR20230167968A (ko) | 점도 감소 부형제 조성물 및 이를 포함하는 저점도 고농축 단백질 제형 | |
| JP2016527200A (ja) | Ｃｄ３７抗体とクロラムブシルの併用 | |
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies | |
| WO2019096233A1 (zh) | 免疫治疗剂、核苷类抗代谢物和铂类联合在制备治疗肿瘤的药物中的用途 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| JPWO2023215674A5 (https=) |